Erin Riggle, MD
Critical Care Medicine · Littleton, CONPI 1003004771
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.7%), speaking fees and education — rather than concentrated in one kind of arrangement. 55 manufacturers reported payments, led by Inari Medical, Inc. at 51.8% of the total. Reporting peaked in 2023 at $14,644 and has fallen 78.3% since, to $3,184 in 2025. Among critical care medicine clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 515 payments — averaging $49.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$13K
- AstraZeneca$3K
- GSK$2K
- United Therapeutics Corporation$846
- Sanofi$794
- Boehringer Ingelheim$730
- plus $6K from 49 others
What the payments were for
- Speaking & faculty fees$11,85047%
- Travel & lodging$880%
- Food & beverage$13,41553%
- Education$1020%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$12,929
- CT THROMBECTOMY SYSTEM KIT$12,929
- Impella$415
- NUCALA$368
- Adempas$244
- TAGRISSO$234
- Da Vinci Surgical System$134
- XARELTO$125
- FASENRA$125
- IMFINZI$125
- ZEPBOUND$123
- Prolastin-C$122
- AIRSUPRA$122
- ELIQUIS$121
- ORENITRAM$120
- TYVASO$120
- REMODULIN$120
- TRELEGY ELLIPTA$117
How this compares
$25,455 in reported general payments places this provider in the 90th percentile of 141 critical care medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 166 | $173,380 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 83 | $45,717 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $38,568 |
| Ambrisentan | 23 | $37,910 |
| Spiriva RespimatTiotropium Bromide | 24 | $36,328 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $30,454 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $29,904 |
| EliquisApixaban | 27 | $25,914 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $8,539 |
| Sildenafil Citrate | 19 | $4,878 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 114 | $2,762 |
| Ventolin HfaAlbuterol Sulfate | 18 | $1,065 |
| Prednisone | 47 | $276 |
| Montelukast Sodium | 25 | $207 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,579 | $249,001305 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $730 | $66,78261 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,736 | $47,10773 claims |
| PfizerEliquis | $60 | $25,91427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 141 critical care medicine providers in Colorado.
Other critical care medicine in Littleton
- Nitin GuptaLittleton$35K
- Paula McDermottLittleton$34K
- Kelly GreeneLittleton$18K
- Alecia BryndaLittleton$3K
- Peter HountrasAurora$86K
- Paul WischmeyerAurora$78K
- Chakradhar KotaruGreenwood Village$61K
- Gregory CosgroveDenver$46K
- Walter ConwellDenver$42K
- David HsiaDenver$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.